However, because of the limited studies on the PARP inhibition of sarcoma, we evaluated the combined effects of a PARP inhibitor and doxorubicin in osteosarcoma cells and showed that the combination of the PARP inhibitor olaparib and doxorubicin was more effective than olaparib or doxorubicin monotherapy. This evidence concerns the gene PARP1 and osteosarcoma.